KORU Medical Systems (NASDAQ:KRMD – Get Free Report) and Omnicell (NASDAQ:OMCL – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Risk and Volatility
KORU Medical Systems has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.
Profitability
This table compares KORU Medical Systems and Omnicell’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KORU Medical Systems | -4.03% | -10.63% | -6.51% |
| Omnicell | 3.13% | 5.66% | 3.57% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KORU Medical Systems | 1 | 0 | 4 | 0 | 2.60 |
| Omnicell | 1 | 1 | 7 | 0 | 2.67 |
KORU Medical Systems presently has a consensus target price of $7.00, indicating a potential upside of 112.12%. Omnicell has a consensus target price of $57.86, indicating a potential upside of 55.82%. Given KORU Medical Systems’ higher probable upside, equities analysts clearly believe KORU Medical Systems is more favorable than Omnicell.
Valuation & Earnings
This table compares KORU Medical Systems and Omnicell”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KORU Medical Systems | $41.13 million | 3.69 | -$2.64 million | ($0.04) | -82.50 |
| Omnicell | $1.18 billion | 1.43 | $2.05 million | $0.84 | 44.20 |
Omnicell has higher revenue and earnings than KORU Medical Systems. KORU Medical Systems is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by insiders. Comparatively, 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Omnicell beats KORU Medical Systems on 11 of the 14 factors compared between the two stocks.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
About Omnicell
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
